Fresolimumab

Fresolimumab
Chemical nomenclature
IUPAC name	Fresolimumab
Routes	Intravenous
Legal status	Investigational

Fresolimumab is an experimental monoclonal antibody designed for the treatment of various fibrotic diseases, including idiopathic pulmonary fibrosis, kidney fibrosis, and cancer-related conditions. It targets transforming growth factor beta (TGF-β), a cytokine that plays a critical role in the development of fibrosis and tumor progression.

Mechanism of Action

Fresolimumab acts by inhibiting the activity of all three isoforms of the transforming growth factor beta (TGF-β), which are involved in cellular proliferation, differentiation, and survival. By blocking TGF-β, fresolimumab may reduce fibrosis and inhibit tumor growth.

Clinical Trials

Fresolimumab has been evaluated in several clinical trials. Early-phase trials have assessed its safety and efficacy in treating conditions such as idiopathic pulmonary fibrosis and renal fibrosis. The results have shown promise, but further research is necessary to fully understand its therapeutic potential and safety profile.

Potential Side Effects

As with all therapeutic proteins, there is a potential for immunogenicity with fresolimumab. Other side effects may include skin reactions, fatigue, and gastrointestinal disturbances. The full spectrum of side effects is still being studied in ongoing clinical trials.

Development Status

As of the last update, fresolimumab remains in the investigational stage and has not yet been approved by regulatory bodies such as the Food and Drug Administration (FDA) for clinical use. Its development is being monitored for potential application in a range of fibrotic diseases.

See Also

• Monoclonal antibodies
• Fibrosis
• Transforming growth factor beta